Background: Our previous publication showed that 9% of patients with a history of myocardial infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant because of non-compliance. This report compares the relative frequency of aspirin resistance between known compliant and non-compliance subjects to demonstrate that non-compliance is the predominant cause of aspirin resistance.
Methods: The difference in the slopes of the platelet prostaglandin agonist (PPA) light aggregation curves off aspirin and 2 hours after observed aspirin ingestion was defined as net aspirin inhibition.
Results: After supposedly refraining from aspirin for 7 days, 46 subjects were judged non-compliant with the protocol. Of the remaining 184 compliant subjects 39 were normals and 145 had a past history of MI. In known compliant subjects there was no difference in net aspirin inhibition between normal and MI subjects. Net aspirin inhibition in known compliant patients was statistically normally distributed. Only 3% of compliant subjects (2 normals and 5 MI) had a net aspirin inhibitory response of less than one standard deviation which could qualify as a conservative designation of aspirin resistance. A maximum of 35% of the 191 post MI subjects could be classified as aspirin resistant and/or non-compliant: 9% aspirin resistant because of non-compliance, 23% non-compliant with the protocol and possibly 3% because of a decreased net aspirin inhibitory response in known compliant patients.
Conclusion: Our data supports the thesis that the predominant cause of aspirin resistance is noncompliance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538501 | PMC |
http://dx.doi.org/10.1186/1479-5876-6-46 | DOI Listing |
Int J Biol Macromol
December 2024
State Key Laboratory of Resource Insects, College of Sericulture, Textile and Biomass Sciences, Southwest University, Chongqing 400715, China. Electronic address:
Traditional wound closure methods often present several issues, including additional puncture wounds, adverse effects from anesthesia, and noticeable scarring. Inspired by embryonic wound healing, a Janus hydrogel (PG/Au-Asp@PCM) is designed to manipulate non-invasive wound closure by photothermal-responsive self-contraction of PG/Au-Asp@PCM, which is attributed to the shape memory behavior of PG/Au-Asp@PCM under near-infrared (NIR). Wherein, gelatin acts as a thermally reversible "switch" and polyacrylamide creates stable and cross-linked "net-points".
View Article and Find Full Text PDFAm Heart J
December 2024
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, China. Electronic address:
Background: It remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD.
Methods: Patients in the OPTION trial were stratified based on the presence of MVD.
Thromb Haemost
December 2024
Internal Medicine, Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of).
Aim To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Methods and results Patients both at high ischaemic and bleeding risks were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFYonsei Med J
December 2024
Department of Hematology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
A 55-year-old male with hemophilia A came to the outpatient clinic with chest pain for several days after overdose injection of coagulation factor. He was a heavy smoker and a chronic alcoholic. An electrocardiogram (ECG) showed no specific change.
View Article and Find Full Text PDFThromb Res
January 2025
Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!